Orthocell jumps as nerve repair tech shows hope for erectile dysfunction post-prostate surgery
Orthocell shares popped +10% as the company reported its flagship nerve repair product, Remplir, is being used by Australian urologists.
The Watchlist
Previous Video
Next Video
FBM
FUTURE BATTERY MINERALS LIMITED
Nick Rathjen, MD & CEO
Nick Rathjen
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online